Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents

Basit Öğe Kaydı
dc.contributor.authorCetin, Bulent
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorBerk, Veli
dc.contributor.authorOzturk, Selcuk Cemil
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorOzkan, Metin
dc.date.accessioned2024-04-24T17:28:15Z
dc.date.available2024-04-24T17:28:15Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: Angiogenesis represents a key element in the pathogenesis of malignancy. There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer treated with vascular endothelial growth factor (VEGF)-targeted therapy. The present study was conducted to establish a prognostic model for patients using an oxaliplatin-based or irinotecan-based chemotherapy plus bevacizumab in metastatic colorectal cancer. Methods: Baseline characteristics and outcomes on 170 patients treated with FOLFIRI or XELOX plus anti-VEGF therapy-naive metastatic colorectal cancer were collected from three Turkey cancer centers. Cox proportional hazards regression was used to identify independent prognostic factors for OS. Results: The median OS for the whole cohort was 19 months (95% CI, 14.3 to 23.6 months). Three of the seven adverse prognostic factors according to the Anatolian Society of Medical Oncology (ASMO) were independent predictors of short survival: serum lactate dehydrogenase (LDH) greater than the upper limit of normal (ULN; p<0.001); neutrophils greater than the ULN (p<0.0014); and progression free survival (PFS) less than 6 months (p=0.001). Conclusion: Serum LDH and neutrophil levels were the main prognostic factors in predicting survival, followed by PFS. This model validates incorporation of components of the ASMO model into patient care and clinical trials that use VEGF-targeting agents.en_US
dc.identifier.doi10.7314/APJCP.2012.13.3.1059
dc.identifier.endpage1063en_US
dc.identifier.issn1513-7368
dc.identifier.issue3en_US
dc.identifier.pmid22631638
dc.identifier.scopus2-s2.0-84871915206
dc.identifier.scopusqualityQ3
dc.identifier.startpage1059en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.3.1059
dc.identifier.urihttps://hdl.handle.net/11468/20376
dc.identifier.volume13en_US
dc.identifier.wosWOS:000306182600057
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectVascular Endothelial Growth Factoren_US
dc.subjectBevacizumaben_US
dc.subjectPrognostic Factorsen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.titlePrognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agentsen_US
dc.titlePrognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu